JP2015500861A5 - - Google Patents

Download PDF

Info

Publication number
JP2015500861A5
JP2015500861A5 JP2014547997A JP2014547997A JP2015500861A5 JP 2015500861 A5 JP2015500861 A5 JP 2015500861A5 JP 2014547997 A JP2014547997 A JP 2014547997A JP 2014547997 A JP2014547997 A JP 2014547997A JP 2015500861 A5 JP2015500861 A5 JP 2015500861A5
Authority
JP
Japan
Prior art keywords
acceptable salt
pharmaceutically acceptable
compound according
independently selected
clause
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014547997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015500861A (ja
JP6062453B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/076275 external-priority patent/WO2013092791A1/en
Publication of JP2015500861A publication Critical patent/JP2015500861A/ja
Publication of JP2015500861A5 publication Critical patent/JP2015500861A5/ja
Application granted granted Critical
Publication of JP6062453B2 publication Critical patent/JP6062453B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014547997A 2011-12-22 2012-12-20 炎症性障害の治療のための新規ジヒドロピリミジノイソキノリノン及びその医薬組成物 Expired - Fee Related JP6062453B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161578979P 2011-12-22 2011-12-22
US61/578,979 2011-12-22
PCT/EP2012/076275 WO2013092791A1 (en) 2011-12-22 2012-12-20 Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (3)

Publication Number Publication Date
JP2015500861A JP2015500861A (ja) 2015-01-08
JP2015500861A5 true JP2015500861A5 (enExample) 2016-02-04
JP6062453B2 JP6062453B2 (ja) 2017-01-18

Family

ID=47520068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014547997A Expired - Fee Related JP6062453B2 (ja) 2011-12-22 2012-12-20 炎症性障害の治療のための新規ジヒドロピリミジノイソキノリノン及びその医薬組成物

Country Status (34)

Country Link
US (5) US8927543B2 (enExample)
EP (3) EP3378862B1 (enExample)
JP (1) JP6062453B2 (enExample)
KR (1) KR102012268B1 (enExample)
CN (1) CN103998448B (enExample)
AR (1) AR089284A1 (enExample)
AU (1) AU2012357067B2 (enExample)
BR (1) BR112014015142B1 (enExample)
CA (1) CA2859578C (enExample)
CL (1) CL2014001664A1 (enExample)
CO (1) CO7010835A2 (enExample)
CR (1) CR20140305A (enExample)
CY (2) CY1119434T1 (enExample)
DK (2) DK3378862T3 (enExample)
EA (1) EA023826B1 (enExample)
ES (2) ES2643379T3 (enExample)
HR (2) HRP20171404T1 (enExample)
HU (1) HUE12812237T4 (enExample)
IL (2) IL233212B (enExample)
IN (1) IN2014MN01033A (enExample)
LT (2) LT2794604T (enExample)
MX (1) MX351681B (enExample)
NI (1) NI201400060A (enExample)
PE (1) PE20141685A1 (enExample)
PH (1) PH12014501178B1 (enExample)
PL (2) PL2794604T3 (enExample)
PT (2) PT3378862T (enExample)
SG (1) SG11201403169PA (enExample)
SI (2) SI2794604T1 (enExample)
TW (1) TWI567073B (enExample)
UA (1) UA111767C2 (enExample)
UY (1) UY34545A (enExample)
WO (1) WO2013092791A1 (enExample)
ZA (1) ZA201404607B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR089284A1 (es) 2011-12-22 2014-08-13 Galapagos Nv Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
SMT201800662T1 (it) 2011-12-22 2019-01-11 Alios Biopharma Inc Nucleotidi, nucleosidi sostituiti e loro analoghi
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9708312B2 (en) 2012-12-20 2017-07-18 Galapagos Nv Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (GPR84 antagonists)
GB201319677D0 (en) * 2013-11-07 2013-12-25 Eth Z Rich Cyclopropanation
GB201411241D0 (en) * 2014-06-25 2014-08-06 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201506894D0 (en) * 2015-04-23 2015-06-10 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US11098071B2 (en) 2017-03-06 2021-08-24 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences GPR84 receptor antagonist and use thereof
EP3403649A1 (en) * 2017-05-16 2018-11-21 Bayer Pharma Aktiengesellschaft Inhibitors and antagonists of gpr84 for the treatment of endometriosis
KR20200088844A (ko) * 2017-11-15 2020-07-23 갈라파고스 엔.브이. 섬유증성 질병 치료에서의 용도를 위한 화합물 및 그의 약학 조성물
PL4077334T3 (pl) 2019-12-19 2025-06-23 Bayer Aktiengesellschaft Pochodne furoindazolu
WO2021123394A1 (en) 2019-12-20 2021-06-24 University Of Copenhagen G protein-coupled receptor modulators and a pharmaceutical composition
JP2023553295A (ja) 2020-11-24 2023-12-21 ガラパゴス・ナムローゼ・フェンノートシャップ 線維性疾患の治療における使用のための化合物及び線維性疾患の治療方法
CA3206499A1 (en) 2021-02-02 2022-08-11 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
CA3211437A1 (en) * 2021-02-23 2022-09-01 Bayer Aktiengesellschaft Furoindazole derivatives as gpr84 antagonists
WO2022194267A1 (zh) * 2021-03-18 2022-09-22 武汉人福创新药物研发中心有限公司 一种gpr84拮抗剂及其制备方法和用途
WO2022218372A1 (zh) * 2021-04-14 2022-10-20 武汉人福创新药物研发中心有限公司 一种二氢嘧啶并异喹啉酮类衍生物及用途
US20240239804A1 (en) 2021-04-29 2024-07-18 Bayer Aktiengesellschaft Furoindazole derivatives as antagonists or inhibitors of gpr84
EP4355743A1 (en) 2021-06-18 2024-04-24 University of Copenhagen Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists
JP7705966B2 (ja) * 2021-06-21 2025-07-10 武漢人福創新薬物研発中心有限公司 Gpr84アンタゴニストとしての三環式化合物
CN115611944A (zh) 2021-07-15 2023-01-17 中国科学院上海药物研究所 不对称gpr84拮抗剂及其用途
WO2023076668A1 (en) * 2021-10-29 2023-05-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for treatment of cancer
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
WO2024083705A1 (en) 2022-10-18 2024-04-25 Bayer Aktiengesellschaft Furoindazole derivatives for the treatment of pain
CN120569392A (zh) * 2022-12-30 2025-08-29 广州市联瑞制药有限公司 三环类化合物及其制备方法和应用
WO2024220480A2 (en) * 2023-04-17 2024-10-24 The Board Of Trustees Of The Leland Stanford Junior University Method for detecting innate immune action in vivo using gpr84-pet
US12194045B1 (en) 2023-06-26 2025-01-14 Verona Pharma Plc Particulate composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2720085A1 (de) 1977-05-05 1978-11-16 Hoechst Ag Pyrimido(6,1-a)isochinolin-2-on- derivate
CA2294244A1 (en) * 1997-07-12 1999-01-21 Cancer Research Campaign Technology Limited Cyclin dependent kinase inhibiting purine derivatives
EP1165556A1 (en) * 1999-03-31 2002-01-02 Vernalis Limited Derivatives of pyrimido[6,1-a]isoquinolin-4-one
JP2007525475A (ja) * 2003-07-08 2007-09-06 スミスクライン・ビーチャム・コーポレイション 新規化学化合物
WO2005050225A2 (en) 2003-10-31 2005-06-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
WO2007027661A2 (en) 2005-09-02 2007-03-08 Arena Pharmaceuticals, Inc. Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20110403A1 (es) 2008-07-31 2011-07-04 Genentech Inc Compuestos biciclicos fusionados de pirimidina en el tratamiento del cancer
JP2011088847A (ja) * 2009-10-21 2011-05-06 Takeda Chem Ind Ltd 三環性化合物およびその用途
AU2012367780B2 (en) 2011-12-22 2017-04-06 Connexios Life Sciences Pvt. Ltd. Derivatives of aza adamantane and uses thereof
BR112014015301A8 (pt) 2011-12-22 2017-07-04 Connexios Life Sciences Pvt Ltd derivados de amida cíclica como inibidores de 11 - beta-hidroxiesteroide desidrogenase e seus usos
SI2794600T1 (en) 2011-12-22 2018-03-30 Novartis Ag 2,3-Dihydro-benzo (1,4) oxazine derivatives and related compounds as phosphoinositide-3 kinase inhibitors (PI3K) for the treatment, e.g. rheumatoid arthritis
AR089284A1 (es) 2011-12-22 2014-08-13 Galapagos Nv Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
US9708312B2 (en) 2012-12-20 2017-07-18 Galapagos Nv Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (GPR84 antagonists)

Similar Documents

Publication Publication Date Title
JP2015500861A5 (enExample)
JP2014523851A5 (enExample)
JP2016525072A5 (enExample)
JP2014530900A5 (enExample)
JP2010525023A5 (enExample)
JP2011502956A5 (enExample)
JP2016532673A5 (enExample)
JP2015506382A5 (enExample)
CA2918284A1 (en) Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
JP2016534063A5 (enExample)
UA112296C2 (uk) Сухий порошковий препарат, який містить інгібітор фосфодіестерази
RU2014115290A (ru) Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов
JP2016505637A5 (enExample)
JP2013520473A5 (enExample)
JP2019513745A5 (enExample)
PH12019500615A1 (en) 5-[2-(PYRIDIN-2-YLAMINO)-1,3-THIAZOL-5-YL]-2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND THEIR USE AS DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA and GAMMA
IL204064A (en) Compounds 4-Formylphiprazine-1-Carboxamidine Efficacy as Muscarinic Receptor Antagonists
RU2006132195A (ru) Комбинация агонистов бета-2 адренорецептора, бензотиазол-2-онов и кортикостероидов, предназначенная для лечения респираторных заболеваний
KR20150013332A (ko) 간세포 암종(hcc) 환자 치료제의 효과적 반응을 결정하기 위한 바이오마커
JP2019536764A5 (enExample)
RU2015121037A (ru) Производные фенилэтилпиридина в качестве ингибиторов pde-4
JP2008531558A5 (enExample)
HUP0400222A2 (hu) PDE-4 inhibitort és H1 receptor antagonistát tartalmazó kombináció és ennek alkalmazása tüdőbetegségek kezelésére alkalmas gyógyszerkészítmény előállítására
US20200181093A1 (en) Pyrimidinone Derivatives and Uses Thereof to Neutralize the Biological Activity of Chemokines
US10570122B2 (en) Compounds with anti-tumoral activity